PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Ann Rheum Dis. 2000 June; 59(6): 468–477.
PMCID: PMC1753160

Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial

Abstract

OBJECTIVES—To compare three therapeutic strategies using slow acting antirheumatic drugs (SAARDs) in early rheumatoid arthritis (RA), for their disease modifying properties, toxicity, and lag time until treatment effect.
METHODS—Patients with recent onset RA from six hospitals were randomly assigned to immediate initiation of one of three treatment strategies: (I) a "mild SAARD with a long lag time" (hydroxychloroquine, if necessary replaced by auranofin); (II) a "potent SAARD with a long lag time" (intramuscular gold, if necessary replaced by D-penicillamine); (III) a "potent SAARD with a short lag time" (methotrexate, if necessary replaced by sulfasalazine). Comparisons included two years of follow up.
RESULTS—All SAARD strategies reduced mean disease activity. A greater percentage of patients improved clinically with strategies II and III than with strategy I: percentages of patients improved on joint score with strategies II and III (79% and 82%, respectively), which was statistically different from strategy I (66%). The same was true for remission percentages: 31% and 24% v 16%, respectively). Longitudinal analysis showed significantly less disability with strategy III, and a lower erythrocyte sedimentation rate with strategy II than with strategy I. In addition, radiological damage after one and two years, was significantly lower in strategies II and III (at two years median scores were 11 and 10 v 14 in strategy I, p<0.05). Toxicity was increased in strategy II compared with the other strategies.
CONCLUSION—Strategy III, comprising methotrexate or sulfasalazine, produced the best results weighing effectiveness and toxicity. Strategy I (hydroxychloroquine or auranofin) was slightly less effective, and strategy II (intramuscular gold or D-penicillamine) was associated with increased toxicity.

Full Text

The Full Text of this article is available as a PDF (181K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Roth SH. Rethinking rheumatic disease therapy. J Rheumatol. 1989 Nov;16(11):1408–1409. [PubMed]
  • Wilske KR, Healey LA. Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis. J Rheumatol Suppl. 1990 Nov;25:4–7. [PubMed]
  • van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, Haanen HC, Hofman DM, van Albada-Kuipers GA, ter Borg EJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med. 1996 Apr 15;124(8):699–707. [PubMed]
  • Nuver-Zwart IH, van Riel PL, van de Putte LB, Gribnau FW. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis. 1989 May;48(5):389–395. [PMC free article] [PubMed]
  • Glennås A, Kvien TK, Andrup O, Clarke-Jenssen O, Karstensen B, Brodin U. Auranofin is safe and superior to placebo in elderly-onset rheumatoid arthritis. Br J Rheumatol. 1997 Aug;36(8):870–877. [PubMed]
  • Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum. 1990 Oct;33(10):1449–1461. [PubMed]
  • Jones G, Brooks PM. Injectable gold compounds: an overview. Br J Rheumatol. 1996 Nov;35(11):1154–1158. [PubMed]
  • Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol. 1997 Mar;36(3):345–352. [PubMed]
  • Situnayake RD, Grindulis KA, McConkey B. Long-term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: a comparison using life-table methods. Ann Rheum Dis. 1987 Mar;46(3):177–183. [PMC free article] [PubMed]
  • Segal R, Caspi D, Tishler M, Wigler I, Yaron M. Short term effects of low dose methotrexate on the acute phase reaction in patients with rheumatoid arthritis. J Rheumatol. 1989 Jul;16(7):914–917. [PubMed]
  • Farr M, Bacon PA, Coppock J, Scott DL. Long term experience of salazopyrin EN in rheumatoid arthritis (RA). Scand J Rheumatol Suppl. 1987;64:37–47. [PubMed]
  • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. [PubMed]
  • Scott DL, Spector TD, Pullar T, McConkey B. What should we hope to achieve when treating rheumatoid arthritis? Ann Rheum Dis. 1989 Mar;48(3):256–261. [PMC free article] [PubMed]
  • van der Heide A, Jacobs JW, Dinant HJ, Bijlsma JW. The impact of endpoint measures in rheumatoid arthritis clinical trials. Semin Arthritis Rheum. 1992 Apr;21(5):287–294. [PubMed]
  • van der Heide A, Jacobs JW, van Albada-Kuipers GA, Kraaimaat FW, Geenen R, Bijlsma JW. Self report functional disability scores and the use of devices: two distinct aspects of physical function in rheumatoid arthritis. Ann Rheum Dis. 1993 Jul;52(7):497–502. [PMC free article] [PubMed]
  • Thompson PW, Silman AJ, Kirwan JR, Currey HL. Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum. 1987 Jun;30(6):618–623. [PubMed]
  • van den Brink HR, van der Heide A, Jacobs JW, van der Veen MJ, Bijlsma JW. Evaluation of the Thompson articular index. J Rheumatol. 1993 Jan;20(1):28–32. [PubMed]
  • Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, Decker JL, Genant HK, Gofton JP, Goodman N, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum. 1985 Dec;28(12):1326–1335. [PubMed]
  • van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989 May 13;1(8646):1036–1038. [PubMed]
  • Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol. 1993 Mar;20(3):561–565. [PubMed]
  • Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R, Jr, Paulus H, Strand V, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727–735. [PubMed]
  • Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum. 1990 Apr;33(4):477–484. [PubMed]
  • Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990 Jan;1(1):43–46. [PubMed]
  • Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239–245. [PubMed]
  • Miedema HS, van der Linden SM, Rasker JJ, Valkenburg HA. National database of patients visiting rheumatologists in The Netherlands: the standard diagnosis register of rheumatic diseases. A report and preliminary analysis. Br J Rheumatol. 1998 May;37(5):555–561. [PubMed]
  • Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967 Aug;20(8):637–648. [PubMed]
  • Clark P, Casas E, Tugwell P, Medina C, Gheno C, Tenorio G, Orozco JA. Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med. 1993 Dec 1;119(11):1067–1071. [PubMed]
  • Suarez-Almazor ME, Russell AS. Parenteral methotrexate or gold for rheumatoid arthritis: a follow up. Clin Exp Rheumatol. 1990 Mar-Apr;8(2):163–166. [PubMed]
  • Situnayake RD, McConkey B. Clinical and laboratory effects of prolonged therapy with sulfasalazine, gold or penicillamine: the effects of disease duration on treatment response. J Rheumatol. 1990 Oct;17(10):1268–1273. [PubMed]
  • Haagsma CJ, Russel FG, Vree TB, Van Riel PL, Van de Putte LB. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. Br J Clin Pharmacol. 1996 Aug;42(2):195–200. [PubMed]
  • van Riel PL, van der Heijde DM, Nuver-Zwart IH, van de Putte LB. Radiographic progression in rheumatoid arthritis: results of 3 comparative trials. J Rheumatol. 1995 Sep;22(9):1797–1799. [PubMed]
  • López-Méndez A, Daniel WW, Reading JC, Ward JR, Alarcón GS. Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum. 1993 Oct;36(10):1364–1369. [PubMed]
  • Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, Weissman BN. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum. 1993 May;36(5):613–619. [PubMed]
  • Drosos AA, Tsifetaki N, Tsiakou EK, Timpanidou M, Tsampoulas C, Tatsis CK, Kotoulas K, Moutsopoulos HM. Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. Clin Exp Rheumatol. 1997 May-Jun;15(3):263–267. [PubMed]
  • Harrison BJ, Symmons DP, Brennan P, Barrett EM, Silman AJ. Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol. 1996 Nov;35(11):1096–1100. [PubMed]
  • Eberhardt K, Rydgren L, Fex E, Svensson B, Wollheim FA. D-penicillamine in early rheumatoid arthritis: experience from a 2-year double blind placebo controlled study. Clin Exp Rheumatol. 1996 Nov-Dec;14(6):625–631. [PubMed]
  • Rau R, Herborn G, Karger T, Menninger H, Elhardt D, Schmitt J. A double blind randomized parallel trial of intramuscular methotrexate and gold sodium thiomalate in early erosive rheumatoid arthritis. J Rheumatol. 1991 Mar;18(3):328–333. [PubMed]
  • Prevoo ML, van Gestel AM, van T Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol. 1996 Nov;35(11):1101–1105. [PubMed]
  • Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997 Aug 2;350(9074):309–318. [PubMed]

Figures and Tables

Figure 1
Mean disability score in 150 patients with available data on disability for all nine measurements in each therapeutic strategy. There was a significant difference between strategies I and III (p = 0.04), and a significant decrease ...
Figure 2
Mean pain score in 243 patients with available data on pain for all nine measurements in each therapeutic strategy. Significant decrease in pain score over time in each strategy, no significant difference between the strategies (p = 0.23) ...
Figure 3
Mean joint score in 247 patients with available data on joint score for all nine measurements in each therapeutic strategy. Significant decrease in joint score over time in each strategy, no significant difference between the strategies (p = 0.30) ...
Figure 4
Mean ESR score in 237 patients with available data on ESR for all nine measurements, in each therapeutic strategy. Significant difference between strategies I and II (p = 0.01), and significant decrease in ESR over time in each ...
Figure 5
Radiological progression in the three strategies. Significant increase over time in each strategy with significant interaction between overall time-treatment effect and strategy effect, showing a faster increase in strategy I than in strategy II (p = 0.03) ...
Figure 6
Percentage of patients in remission at each measurement in time. Remission is defined as morning stiffness ≤15 min, pain score ≤10 mm, joint score ≤10, and ESR ≤30 mm/ 1st h.

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group